Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 1165

1.

Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life.

Adamkiewicz TV, Silk BJ, Howgate J, Baughman W, Strayhorn G, Sullivan K, Farley MM.

Pediatrics. 2008 Mar;121(3):562-9. doi: 10.1542/peds.2007-0018.

PMID:
18310206
2.

Herd immunity and pneumococcal conjugate vaccine: a quantitative model.

Haber M, Barskey A, Baughman W, Barker L, Whitney CG, Shaw KM, Orenstein W, Stephens DS.

Vaccine. 2007 Jul 20;25(29):5390-8. Epub 2007 May 22.

PMID:
17583392
3.

Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente.

Black S, Shinefield H, Baxter R, Austrian R, Bracken L, Hansen J, Lewis E, Fireman B.

Pediatr Infect Dis J. 2004 Jun;23(6):485-9.

PMID:
15194827
4.

Population-based surveillance for childhood invasive pneumococcal disease in the era of conjugate vaccine.

Hsu K, Pelton S, Karumuri S, Heisey-Grove D, Klein J; Massachusetts Department of Public Health Epidemiologists.

Pediatr Infect Dis J. 2005 Jan;24(1):17-23.

PMID:
15665705
5.

Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects.

Lloyd A, Patel N, Scott DA, Runge C, Claes C, Rose M.

Eur J Health Econ. 2008 Feb;9(1):7-15. Epub 2007 Mar 2.

PMID:
17333089
6.

Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway.

Vestrheim DF, Løvoll O, Aaberge IS, Caugant DA, Høiby EA, Bakke H, Bergsaker MR.

Vaccine. 2008 Jun 19;26(26):3277-81. doi: 10.1016/j.vaccine.2008.03.087. Epub 2008 Apr 18.

PMID:
18456376
7.

Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine.

Black SB, Shinefield HR, Hansen J, Elvin L, Laufer D, Malinoski F.

Pediatr Infect Dis J. 2001 Dec;20(12):1105-7.

PMID:
11740313
8.
9.

Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.

Tyo KR, Rosen MM, Zeng W, Yap M, Pwee KH, Ang LW, Shepard DS.

Vaccine. 2011 Sep 2;29(38):6686-94. doi: 10.1016/j.vaccine.2011.06.091. Epub 2011 Jul 13.

PMID:
21745516
10.

Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.

Wisløff T, Abrahamsen TG, Bergsaker MA, Løvoll Ø, Møller P, Pedersen MK, Kristiansen IS.

Vaccine. 2006 Jul 17;24(29-30):5690-9. Epub 2006 May 5.

PMID:
16735083
11.

Effect of community-wide conjugate pneumococcal vaccine use in infancy on nasopharyngeal carriage through 3 years of age: a cross-sectional study in a high-risk population.

Millar EV, O'Brien KL, Watt JP, Bronsdon MA, Dallas J, Whitney CG, Reid R, Santosham M.

Clin Infect Dis. 2006 Jul 1;43(1):8-15. Epub 2006 May 18.

12.

A conjugate vaccine for the prevention of pediatric pneumococcal disease.

Murray D, Jackson C.

Mil Med. 2002 Aug;167(8):671-7. Review.

PMID:
12188240
13.

Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine.

Halasa NB, Shankar SM, Talbot TR, Arbogast PG, Mitchel EF, Wang WC, Schaffner W, Craig AS, Griffin MR.

Clin Infect Dis. 2007 Jun 1;44(11):1428-33. Epub 2007 Apr 18.

14.

Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.

Melegaro A, Edmunds WJ.

Vaccine. 2004 Oct 22;22(31-32):4203-14.

PMID:
15474710
15.

Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction--eight states, 1998-2005.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2008 Feb 15;57(6):144-8.

16.

Surveillance for invasive pneumococcal disease during 2000-2005 in a population of children who received 7-valent pneumococcal conjugate vaccine.

Black S, France EK, Isaacman D, Bracken L, Lewis E, Hansen J, Fireman B, Austrian R, Graepel J, Gray S, Klein NP.

Pediatr Infect Dis J. 2007 Sep;26(9):771-7.

PMID:
17721369
17.
18.

Prediction of the potential benefit of different pneumococcal conjugate vaccines on invasive pneumococcal disease in German children.

von Kries R, Hermann M, Hachmeister A, Siedler A, Schmitt HJ, Al-Lahham A, Reinert RR.

Pediatr Infect Dis J. 2002 Nov;21(11):1017-23.

PMID:
12442022
19.

Changing characteristics of invasive pneumococcal disease in Metropolitan Atlanta, Georgia, after introduction of a 7-valent pneumococcal conjugate vaccine.

Albrich WC, Baughman W, Schmotzer B, Farley MM.

Clin Infect Dis. 2007 Jun 15;44(12):1569-76. Epub 2007 May 8.

20.

Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine.

Lacapa R, Bliss SJ, Larzelere-Hinton F, Eagle KJ, McGinty DJ, Parkinson AJ, Santosham M, Craig MJ, O'Brien KL.

Clin Infect Dis. 2008 Aug 15;47(4):476-84. doi: 10.1086/590001.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk